Wells Fargo & Company Renovo Rx, Inc. Transaction History
Wells Fargo & Company
- $410 Billion
- Q1 2024
A detailed history of Wells Fargo & Company transactions in Renovo Rx, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 69 shares of RNXT stock, worth $88. This represents 0.0% of its overall portfolio holdings.
Number of Shares
69
Previous 67
2.99%
Holding current value
$88
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding RNXT
# of Institutions
13Shares Held
1.31MCall Options Held
0Put Options Held
0-
Bank Of The West975KShares$1.25 Million0.27% of portfolio
-
Nixon Peabody Trust CO Boston, MA97.2KShares$124,3710.01% of portfolio
-
Geode Capital Management, LLC Boston, MA67.1KShares$85,8720.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA56.7KShares$72,6230.0% of portfolio
-
Charles Schwab Investment Management Inc San Francisco, CA49.2KShares$63,0160.0% of portfolio
About RenovoRx, Inc.
- Ticker RNXT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 9,066,860
- Market Cap $11.6M
- Description
- RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. RenovoRx, In...